copycat Posted July 7, 2007 Share Posted July 7, 2007 The IOM company ProMetic has concluded a US$1.7 Million Agreement With European Plasma Fractionator to Develop Plasma Prion Removal Process - a process to Reduce Risk of Variant Creutzfeldt-Jakob Disease from Plasma-Derived Products About vCJD vCJD and Bovine Spongiform Encephalopathy (BSE) are caused by abnormal prions or rogue proteins. Prion diseases are known to have long incubation periods and it is possible that a person could be silently infected for more than several decades before developing symptoms of the disease. During this time they pose a potential risk to others through blood transfusion and contamination of surgical and medical instruments. vCJD is characterized by the accumulation of large deposits in the brain and the nervous system of the misfolded prion protein. The resulting damage causes sponge-like holes to appear in the brain causing a fatal degenerative CNS disorder. Such abnormal prion proteins may be sufficient to transmit the disease. Although some people's genetic make-up may protect them, at least 89% of the population may be susceptible to vCJD. About ProMetic BioSciences Ltd Using its unique and proprietary Mimetic LigandTM technology, PBL specializes in the development and manufacture of robust affinity separation materials which provide very high levels of purification. This is achieved by use of small chemical affinity ligands designed to bind a target biomolecule specifically and reversibly. In view of their use for the production of therapeutics, ProMetic's affinity products are manufactured to strict quality standards at PBL's GMP-compliant manufacturing facility on the Isle of Man, which completed a pounds sterling 1.5 million expansion in 2005. PBL also operates an R&D laboratory located on the Cambridge Science Park, United Kingdom. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.